{"url_path":"/sec/vvos/8-k/2026-06-25/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-030190-index.html","accession_number":"0001493152-26-030190","cik":"0001716166","ticker":"VVOS","issuer_name":"Vivos Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-030190-index.html","primary_entity_key":"0001716166","primary_entity_name":"Vivos Therapeutics, Inc."},"word_count":135,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n**(d)\nExhibits.**\n\n** **\n\n**Exhibit\nNo.**\n \n**Description**\n\n10.1\n \n[Exchange Agreement dated as of June 5, 2026, between Vivos Therapeutics, Inc. and Streeterville Capital, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed June 8, 2026).](https://www.sec.gov/Archives/edgar/data/1716166/000149315226027641/ex10-1.htm)\n\n \n \n \n\n10.2*\n \n[Letter Agreement dated as of June 18, 2026, between Vivos Therapeutics, Inc. and Streeterville Capital, LLC.](ex10-2.htm)\n\n \n \n \n\n99.1*\n \n[Press Release, dated June 22, 2026.](ex99-1.htm)\n\n \n \n \n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n*\nFiled herewith\n\n \n\n \n\n \n\n** **\n\n**SIGNATURE**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n**VIVOS\nTHERAPEUTICS, INC.**\n \n \n\n \n \n \n\nDated:\nJune 25, 2026\nBy:\n*/s/\nR. Kirk Huntsman*\n\n \nName:\nR.\nKirk Huntsman\n\n \nTitle:\nChief\nExecutive Officer"}